Merus N.V. (NASDAQ:MRUS) COO Sells $368,225.00 in Stock

Merus N.V. (NASDAQ:MRUS - Get Free Report) COO Peter B. Silverman sold 6,695 shares of the company's stock in a transaction that occurred on Wednesday, July 9th. The stock was sold at an average price of $55.00, for a total transaction of $368,225.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Peter B. Silverman also recently made the following trade(s):

• On Thursday, July 10th, Peter B. Silverman sold 16,805 shares of Merus stock. The stock was sold at an average price of $55.00, for a total transaction of $924,275.00.
• On Friday, June 20th, Peter B. Silverman sold 34,000 shares of Merus stock. The shares were sold at an average price of $52.76, for a total transaction of $1,793,840.00.

Merus Trading Down 1.1%

Shares of Merus stock traded down $0.61 during mid-day trading on Friday, hitting $54.50. 315,839 shares of the stock were exchanged, compared to its average volume of 732,777. The company has a 50-day simple moving average of $50.76 and a 200 day simple moving average of $45.64. Merus N.V. has a twelve month low of $33.19 and a twelve month high of $62.98. The stock has a market capitalization of $3.77 billion, a price-to-earnings ratio of -13.36 and a beta of 1.00.

Merus (NASDAQ:MRUS - Get Free Report) last released its earnings results on Wednesday, May 14th. The biotechnology company reported ($1.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.17) by ($0.23). Merus had a negative return on equity of 35.99% and a negative net margin of 506.73%. The company had revenue of $26.49 million during the quarter, compared to analyst estimates of $7.82 million. Equities research analysts forecast that Merus N.V. will post -3.85 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research firms have recently weighed in on MRUS. William Blair reiterated an "outperform" rating on shares of Merus in a research note on Monday, April 28th. Needham & Company LLC reiterated a "buy" rating and issued a $75.00 price objective on shares of Merus in a research note on Monday, May 19th. Wells Fargo & Company cut their price objective on shares of Merus from $91.00 to $89.00 and set an "overweight" rating on the stock in a research note on Thursday, May 8th. Wall Street Zen upgraded shares of Merus from a "sell" rating to a "hold" rating in a research note on Saturday. Finally, Guggenheim reissued a "buy" rating and set a $109.00 price target on shares of Merus in a report on Friday, March 28th. One investment analyst has rated the stock with a hold rating, twelve have given a buy rating and two have assigned a strong buy rating to the company's stock. According to MarketBeat, the company has an average rating of "Buy" and a consensus price target of $84.64.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in MRUS. GAMMA Investing LLC raised its holdings in Merus by 2,153.6% in the first quarter. GAMMA Investing LLC now owns 631 shares of the biotechnology company's stock valued at $27,000 after acquiring an additional 603 shares in the last quarter. State of Wyoming acquired a new stake in Merus in the fourth quarter valued at $48,000. Wells Fargo & Company MN raised its holdings in Merus by 27.3% in the fourth quarter. Wells Fargo & Company MN now owns 1,400 shares of the biotechnology company's stock valued at $59,000 after acquiring an additional 300 shares in the last quarter. GF Fund Management CO. LTD. acquired a new stake in Merus in the fourth quarter valued at $60,000. Finally, Caitong International Asset Management Co. Ltd raised its holdings in Merus by 955.3% in the first quarter. Caitong International Asset Management Co. Ltd now owns 1,794 shares of the biotechnology company's stock valued at $76,000 after acquiring an additional 1,624 shares in the last quarter. 96.14% of the stock is owned by institutional investors and hedge funds.

About Merus

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.